US equities |
INTC $65.00 ▼-29.40% AMZN $238.51 ▼-2.17% MU $880.71 ▼-5.73% NVDA $205.36 ▼-3.88% SNDK $1,169.97 ▼-12.04% GOOGL $281.86 ▼-0.69% SPCX $137.99 ▼-4.10% TSLA $400.07 ▼-0.80%
FinancialContent

IGC Pharma, Inc. Common Stock (NY:IGC)

0.1861 -0.0131 (-6.58%)
Delayed Quote Updated: 12:01 PM EDT, Oct 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about IGC Pharma, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
News headline image
IGC Pharma Secures Psilocybin Research Authorization, Expanding Focus on Neuropsychiatric Symptoms in Dementia
Via ACCESS Newswire
News headline image
New to The Street to Broadcast Tonight on Bloomberg at 6:30 PM EST - Show #744 Featuring Virtuix Holdings (NASDAQ:VTIX), Neonc Technologies Holdings (NASDAQ:NTHI), Medicus Pharma (NASDAQ:MDCX), YY Group Holding (NASDAQ:YYGH), and Vivos Therapeutics
Via ACCESS Newswire
News headline image
IGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial, Entering Final Phase Ahead of Enrollment Completion and Data Readout
Via ACCESS Newswire
News headline image
IGC Pharma Adds Tandem Clinical Research to the CALMA Trial for Agitation in Alzheimer's Disease
Via ACCESS Newswire
News headline image
IGC Pharma Launches Strategic National Media Partnership with New to The Street to Expand Investor Awareness
Via ACCESS Newswire
News headline image
New to The Street Broadcasts Show #740 on Bloomberg Television at 6:30 PM EST Featuring Medicus (MDCX), Acme Markets- Canton Foundation, Alpha Ton Capital (ATON), and Virtuix Holdings (NASDAQ:VTIX)
Via ACCESS Newswire
News headline image
New to The Street and IGC Pharma (NYSE American:IGC) Launch Strategic 12-Part National Media Partnership to Accelerate Investor Awareness and Market Positioning
Via ACCESS Newswire
News headline image
IGC Pharma Reports Financial Results and Clinical Progress for the Period Ended December 31, 2025
Via ACCESS Newswire
News headline image
IGC Pharma to Showcase AI Platform with Alzheimer's Disease Data Initiative at ADPD 2026
Via ACCESS Newswire
News headline image
IGC Pharma Files Utility Patent Applications Covering AI-Based Data Harmonization Architecture Supporting Alzheimer's Research
Via ACCESS Newswire
News headline image
IGC Pharma Notes Updated Research Coverage from Ascendiant Capital Markets
Via ACCESS Newswire
News headline image
IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial
Via ACCESS Newswire
News headline image
IGC Pharma Secures North American Composition Protection for IGC-AD1 as Phase 2 CALMA Enrollment Advances
Via ACCESS Newswire
News headline image
IGC Pharma to Participate in Fireside Chat With Ascendiant Capital Markets
Via ACCESS Newswire
News headline image
IGC Pharma Announces Equity Research Update by Alliance Global Partners
Via ACCESS Newswire
News headline image
IGC Pharma Expands Phase 2 CALMA Trial into Colombia's Premier Alzheimer's Research Center
Via ACCESS Newswire
News headline image
IGC Pharma Reaches 70% Enrollment in Phase 2 CALMA Trial Evaluating IGC-AD1 for Alzheimer's Agitation
Via ACCESS Newswire
News headline image
IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Trial Site at Integrative Clinical Trials in New York
Via ACCESS Newswire
News headline image
IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Site at Dominion Medical Associates, a Lightship Network Site, in Richmond, Virginia
Via ACCESS Newswire
News headline image
IGC Pharma Aligns Fiscal Year with Calendar Year to Enhance U.S. Investor Transparency and Comparability
Via ACCESS Newswire
News headline image
IGC Pharma Raises Capital to Advance IGC-AD1 Phase 2 Trial
Via ACCESS Newswire
News headline image
IGC Pharma Secures New U.S. Patent as Pharmaceutical Cannabinoids Gain Regulatory Momentum
Via ACCESS Newswire
News headline image
IGC Pharma Positions as a Singular Beneficiary of Emerging Federal Momentum Toward Schedule III Cannabinoid Medicines
Via ACCESS Newswire
News headline image
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock. Raising P/T to $4.75."
Via ACCESS Newswire
News headline image
IGC Pharma Reports 65% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial
Via ACCESS Newswire
News headline image
IGC Pharma Announces Publication of Landmark Caregiver Book on Alzheimer's Disease
Via ACCESS Newswire
News headline image
IGC Pharma Leverages MINT-AD to Identify Socioeconomic Risk Factors Driving Alzheimer's and Aging Trends
Via ACCESS Newswire
News headline image
IGC Pharma Reports Accelerated Q2 Progress and Strengthened Financial Focus: CALMA Trial Passes 50% Enrollment Milestone, Strategic Divestiture Optimizes Capital
Via ACCESS Newswire
News headline image
USPTO Grants IGC Pharma Patent Covering IGC-AD1 for Novel Composition Targeting Alzheimer's Disease and Central Nervous System Disorders
Via ACCESS Newswire
News headline image
IGC Pharma to Host Mid-Year Fiscal 2026 Shareholder Update Call on November 17, 2025
Via ACCESS Newswire
< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >